Efficacy for the Annual Relapse Rate after the Immunosuppressive Therapy in Patients Associated with Anti-AQP4 or Anti-MOG Antibody-Positive Optic Neuritis

Table 3

The efficacy of immunosuppressive therapy.

	At the initiation of immunosuppressive therapy	At final visit
Median ARR of ON (first-third quartile)	0.33 (0–0.45)	0 (0–0)
Median ARR of ON, myelitis, and encephalitis episode (first-third quartile)	0.37 (0.17–0.55)	0 (0–0.13)
Mean PSL dosage (mg/day) (SD)	17.8 (7.1)	6.2 (2.4)
Mean logMAR BCVA (SD)
Dominant eye	−0.1 (0.2)	−0.1 (0.2)
Nondominant eye	0.9 (1.0)	0.9 (1.0)
Mean GCL + thickness (μm) (SD)
Dominant eye	59.5 (12.5)	57.5 (10.5)
Nondominant eye	49.8 (15.3)	45.4 (14.5)
Mean cpRNFL thickness (μm) (SD)
Dominant eye	71.2 (21.0)	74.4 (18.1)
Nondominant eye	59.9 (22.1)	58.0 (13.4)

ARR: annualized relapse rate, ON: optic neuritis, PSL: prednisolone, SD: standard deviation, BCVA: best-corrected visual acuity, GCL: ganglion cell layer, cpRNFL: circumpapillary retinal nerve fiber layer.